Restoring a normal sexual response: The ultimate goal of erectile dysfunction therapy

European Urology, Supplement

Volumn 1, Issue 8, 2002, Pages 19-24

  Porst, Hartmut ^a  

^a Private Practice   (Germany)

Author keywords

Aging; Erectile dysfunction; Male sexuality; Pharmacokinetics; Phosphodiesterase type 5 inhibitors; Tadalafil

Indexed keywords

TADALAFIL;

AGING; AREA UNDER THE CURVE; COMORBIDITY; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPLASIA; ERECTILE DYSFUNCTION; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE;

EID: 0036870620     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00114-8     Document Type: Conference Paper

References (22)

1. Jardin A, Wagner G, Khoury S, Giuliano F, Goldstein I, Padma-Nathan H, editors. Recommendations of the First International Consultation on Erectile Dysfunction, co-sponsored by the World Health Organization (WHO). Plymouth: Health Publications Ltd., 2000, p. 709-26.
2. Chun J, Carson III CC. Physician-patient dialogue and clinical evaluation of erectile dysfunction. Urol Clin North Am 2001;28:249-58.
3. Mobley DF, Baum N. When patients request the impotence pill: tips for office evaluation and treatment. Postgrad Med 1998;104:55-66.
4. Giuliano F, Chevret-Measson M, Tsatsaris A, Reitz C, Murino M, Thonneau P. Prevalence of erectile dysfunction: results of an epidemiological survey of a representative sample of 1004 men. Eur Urol 2002;42:382-9.
5. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-6.
6. Martin-Morales A, Sanchez-Cruz JJ, Sáenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001;166:569-75.
7. Parazzini F, Menchini Fabris F, Bortolotti A, Calabro A, Chatenoud L, Colli E, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000;37:43-9.
8. Meuleman EJ, Donkers LH, Robertson C, Keech M, Boyle P, Kiemeney LA. Erectile dysfunction: prevalence and effect on the quality of life: Boxmeer study. Ned Tijdschr Geneeskd 2001;145: 576-81.
9. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
10. Fugl-Meyer AR, Lodnert G, Branholm IB, Fugl-Meyer KS. On life satisfaction in male erectile dysfunction. Int J Impot Res 1997;9:141-8.
11. Wagner G, Fugl-Meyer KS, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Impot Res 2000;12(Suppl 4):S144-6.
12. NIH Consensus Conference: Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
13. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997;157:2135-8.
14. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998;159:1541-7.
15. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000;12:305-11.
16. Kumamoto Y, Tsukamoto T, Satoh Y, Horita H. Epidemiological study on aging changes of sexual activity in Japanese men and women. The Aging Male 2000;3(Suppl 1):9 [abstract 018].
17. Taylor Jr HA. Sexual activity and the cardiovascular patient: guidelines. Am J Cardiol 1999;84:6N-10N.
18. Rowland DL, Greenleaf W, Mas M, Myers L, Davidson JM. Penile and finger sensory thresholds in young, aging, and diabetic males. Arch Sex Behav 1989;18:1-12.
19. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Int J Impot Res 2001;13(Suppl 4):S43 [abstract 120].
20. Padma-Nathan H, Rosen R, Shabsigh R, Saikali K, Watkins V, Pullman W. Tadalafil (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). Int J Impot Res 2001;13(Suppl 4):S33 [abstract 88].
21. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin A, Whitaker S. Efficacy and safety of tadalafil in the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002;168:1332-6.
22. Porst H, Rosen RC, Padma-Nathan H, Varanese L, Anglin G, Giuliano F. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J Urol 2002; 167(Suppl 4):177 [abstract 709].